AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

The drugmaker’s U.S. plans comes on the heels of a rough quarter, with lower vaccine demand driving down Q3 sales by 15% year ...

When Hurricane Helene damaged western North Carolina in September, filling medical facilities with people who couldn’t be ...

of GSK in Research Triangle Park, North Carolina, and colleagues. No problems with safety or tolerability were identified, the group reported in Annals of the Rheumatic Diseases, leading them to ...

The VoxScan app allows users to interact with MRI and CT scans on everyday devices, aiming to improve patient outcomes and ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), following a string of exits by companies including Pfizer, UCB, WuXi AppTec and ...

The Lupus Foundation of America works to improve the quality of life for all people affected by lupus through programs of research, education, support and advocacy. Join our lupus registry, RAY, and ...

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...

In a strategic move to enhance their immunology portfolio, GSK has announced an agreement to acquire experimental therapy CMG1A46 from Chimagen Biosciences, a privately-held biotechnology company ...